Current industrial practices and regulatory requirements to assess analyte and reagent stability using ligand-binding assays / Jin Wang, William Nowatzke, Mark Ma
Specific guidelines on bioanalytical method validation for drug development support are recommended by regulatory agencies. Regarding stability assessment, US FDA states that Stability procedures should evaluate the stability of the analytes during sample collection and handling, after long-term (frozen at the intended storage temperature) and short-term (bench-top, room temperature) storage, and after going through freeze and thaw cycles and the analytical process. Additional regulatory considerations are discussed including topics such as analyte and reagent stability. This article reviews the regulatory requirements as issued by the USA (FDA), Europe (EMA) and Japan (MHLW), for stability studies where bioanalytical methods are used to support drug development programs and summarizes the current industry standard for conducting stability studies when utilizing ligand-binding assays.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Bioanalysis - 7(2015), 11, Seite 1371- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Jin [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (14 p) |
|---|
| doi: |
10.4155/bio.15.52 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL001061933 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL001061933 | ||
| 003 | DE-627 | ||
| 005 | 20230430081549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio.15.52 |2 doi | |
| 035 | |a (DE-627)KFL001061933 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/bio.15.52 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Wang, Jin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current industrial practices and regulatory requirements to assess analyte and reagent stability using ligand-binding assays |c Jin Wang, William Nowatzke, Mark Ma |
| 264 | 1 | |c 2015 | |
| 300 | |a 1 Online-Ressource (14 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Specific guidelines on bioanalytical method validation for drug development support are recommended by regulatory agencies. Regarding stability assessment, US FDA states that Stability procedures should evaluate the stability of the analytes during sample collection and handling, after long-term (frozen at the intended storage temperature) and short-term (bench-top, room temperature) storage, and after going through freeze and thaw cycles and the analytical process. Additional regulatory considerations are discussed including topics such as analyte and reagent stability. This article reviews the regulatory requirements as issued by the USA (FDA), Europe (EMA) and Japan (MHLW), for stability studies where bioanalytical methods are used to support drug development programs and summarizes the current industry standard for conducting stability studies when utilizing ligand-binding assays | ||
| 700 | 1 | |a Nowatzke, William |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Mark |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d London : Future Science, 2009 |g 7(2015), 11, Seite 1371- |h Online-Ressource |w (DE-627)KFL000038172 |w (DE-600)2571813-7 |w (DE-576)398101434 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2015 |g number:11 |g pages:1371- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/bio.15.52 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2015 |e 11 |h 1371- | ||